Guru’s firm also gains a position in Bristol-Myers Squibb following its acquisition of Celgene Continue reading...
Following the new deals in the healthcare space, a few biotech ETFs hit new highs.
Investor's largest sales of the 4th quarter Continue reading...
GAITHERSBURG, Md., Dec. 16, 2019 -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune.
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Bristol-Myers Squibb Company and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
Moody's Investors Service ("Moody's") withdrew the A3 senior unsecured ratings of Celgene Corporation ("Celgene"). Celgene is a subsidiary of Bristol-Myers Squibb Company ("Bristol"). The majority of Celgene's debt was exchanged into direct obligations of Bristol through an exchange offer.
Amgen stock is consolidating as it takes a two-pronged approach to coronavirus treatment, partnering with Adaptive Biotechnologies and testing Otezla in Covid-19. Is Amgen stock a buy?
Bristol-Myers shares edged higher Monday after the group said a new cancer treatment, which it acquired through its $74 billion takeover of Celgene Corp., had solid results from an early clinical trial. Bristol-Myers said a study presented to the American Society of Hematology Conference in Orlando, Florida showed a 53% complete response rate for patients with relapsed or refractory large B-cell lymphoma treated with liso-cel. The new treatment, a so-called chimeric antigen receptor T-cell, or " CAR-T" therapy, was acquired from the immunotherapy portfolio of Celgene last year.
Guru’s positions in Celgene, Altaba were also eliminated Continue reading...
By Geoffrey Smith
SAN DIEGO, CA / ACCESSWIRE / January 7, 2020 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Celgene Corporation (CELG) shares. Investors, who purchased shares of Celgene Corporation (CELG) in 2016 or earlier and continue to hold any of your NASDAQ: CELG shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. On March 29, 2018, a lawsuit was filed against Celgene Corporation over alleged securities laws violations.
Health care-focused fund's largest sales of the 4th quarter Continue reading...
Pharmaceutical company Bristol Myers advanced in 2019 despite shareholder opposition to its Celgene buyout. Now that Bristol has officially acquired Celgene, is it time to buy BMY stock?
Bristol-Myers Squibb Co's head of strategy and business development Paul Biondi left the company last month just as it was completing its $74 billion acquisition of biotech Celgene Corp, the company said on Thursday. Biondi joined Bristol-Myers in 2002 and had been in charge of business development, helping the company pursue strategic partnerships and deals, since 2015. Bristol-Myers announced the Celgene acquisition last January and the deal closed on Nov. 28.
Investor's largest sales of the 4th quarter. Continue reading...
Discussion of the Bristol-Myers contingent value right Continue reading...
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Celgene Corporation and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
Firm’s largest sales of the 4th quarter Continue reading...
Firm's largest sales of the 4th quarter Continue reading...
Just months after its first product was approved by the FDA, Cambridge’s Acceleron Pharma is closer to executing a one-two punch after announcing new clinical trial data this week.